| Literature DB >> 34330897 |
Georgios I Laliotis1,2,3,4, Evangelia Chavdoula5,6, Maria D Paraskevopoulou7, Abdul Kaba5,6, Alessandro La Ferlita5,6,8, Satishkumar Singh6,9, Vollter Anastas5,6,10, Keith A Nair5,6, Arturo Orlacchio5,6, Vasiliki Taraslia7,11, Ioannis Vlachos12,13, Marina Capece5,6, Artemis Hatzigeorgiou12, Dario Palmieri5,6, Christos Tsatsanis14,15, Salvatore Alaimo8, Lalit Sehgal6,9, David P Carbone6,16, Vincenzo Coppola5,6, Philip N Tsichlis17,18,19.
Abstract
AKT-phosphorylated IWS1 regulates alternative RNA splicing via a pathway that is active in lung cancer. RNA-seq studies in lung adenocarcinoma cells lacking phosphorylated IWS1, identified a exon 2-deficient U2AF2 splice variant. Here, we show that exon 2 inclusion in the U2AF2 mRNA is a cell cycle-dependent process that is regulated by LEDGF/SRSF1 splicing complexes, whose assembly is controlled by the IWS1 phosphorylation-dependent deposition of histone H3K36me3 marks in the body of target genes. The exon 2-deficient U2AF2 mRNA encodes a Serine-Arginine-Rich (RS) domain-deficient U2AF65, which is defective in CDCA5 pre-mRNA processing. This results in downregulation of the CDCA5-encoded protein Sororin, a phosphorylation target and regulator of ERK, G2/M arrest and impaired cell proliferation and tumor growth. Analysis of human lung adenocarcinomas, confirmed activation of the pathway in EGFR-mutant tumors and showed that pathway activity correlates with tumor stage, histologic grade, metastasis, relapse after treatment, and poor prognosis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34330897 PMCID: PMC8324843 DOI: 10.1038/s41467-021-24795-1
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919